Insulin, Neurogenetics and Memory in Alzheimer's Disease

Phase 2

Completed

• Conditions: Alzheimer Disease

• Registration Number: NCT00018382
• Lead Sponsor: US Department of Veterans Affairs

Brief Summary

This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

Detailed Description

Not available

Study Timeline

• Study Start: 1999-10
• Study First Submitted: 2001-07-03
• Study First Submitted QC: 2001-07-04
• Study First Posted: 2001-07-05
• Study Completion: 2003-03
• Status Verified: 2004-12
• Last Update Submitted: 2009-01-20
• Last Update Posted: 2009-01-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

VA Puget Sound Health Care System; 🇺🇸 Seattle, Washington, United States